UY27678A1 - Sal agonista del receptor b3 andrenérgico, sus formulaciones y usos. - Google Patents

Sal agonista del receptor b3 andrenérgico, sus formulaciones y usos.

Info

Publication number
UY27678A1
UY27678A1 UY27678A UY27678A UY27678A1 UY 27678 A1 UY27678 A1 UY 27678A1 UY 27678 A UY27678 A UY 27678A UY 27678 A UY27678 A UY 27678A UY 27678 A1 UY27678 A1 UY 27678A1
Authority
UY
Uruguay
Prior art keywords
salt
monohydrate
pharmaceutical compositions
andrenérgico
formulations
Prior art date
Application number
UY27678A
Other languages
English (en)
Inventor
Joseph F Krzyzaniak
Jennifer A Lafontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27678A1 publication Critical patent/UY27678A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona la sal de tosilato de (R)-2-(2-(4-axasol-4-ilfenoxi)etilamino)-1-piridin-3iletano), el monohidrato de dicha sal, procedimientos útiles en la preparación de dicha sal y dicho monohidrato, composiciones farmacéuticas que comprenden dicha sal, o dicho monohidrato, procedimientos para tratar enfermedades, afecciones y trastornos en un mamífero mediados por el receptor B3 adrenérgico utilizando dicha sal, dicho monohidrato o dichas composiciones farmacéuticas; y procedimientos para aumentar el contenido de carne magra en animales comestibles utilizando dicha sal, dicho monohidrato o dichas composiciones farmacéuticas.
UY27678A 2002-02-27 2003-02-25 Sal agonista del receptor b3 andrenérgico, sus formulaciones y usos. UY27678A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36024802P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
UY27678A1 true UY27678A1 (es) 2003-10-31

Family

ID=27766205

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27678A UY27678A1 (es) 2002-02-27 2003-02-25 Sal agonista del receptor b3 andrenérgico, sus formulaciones y usos.

Country Status (8)

Country Link
AR (1) AR038603A1 (es)
AU (1) AU2003248355A1 (es)
GT (1) GT200300044A (es)
PA (1) PA8567601A1 (es)
PE (1) PE20030900A1 (es)
TW (1) TW200305414A (es)
UY (1) UY27678A1 (es)
WO (1) WO2003072571A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CA2423792A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
AR038603A1 (es) 2005-01-19
PA8567601A1 (es) 2003-12-10
PE20030900A1 (es) 2003-10-25
AU2003248355A1 (en) 2003-09-09
GT200300044A (es) 2003-09-22
WO2003072571A1 (en) 2003-09-04
TW200305414A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
ECSP077421A (es) Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
ATE469897T1 (de) Indazolcarbonsäureamidverbindungen
ES2337596T3 (es) Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
CY1113159T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
BRPI0608012A2 (pt) método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
BRPI0510808A (pt) derivados de benzonitrila para tratar fragilidade musculoesquelética
CU20200012A7 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
MX2022002056A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
TN2017000026A1 (en) Substituted bicyclic compounds
CL2011001258A1 (es) Sales de adicion de acido citrico de (r)-5-((e)-2-pirrolidin-3-il vinil)pirimidina; formas polimorficas monocitrato; composicion farmaceutica que las comprende; y su uso en la prevencion o en el tratamiento del dolor, inflamacion o un trastorno del sistema nervioso central.
PE20211387A1 (es) Compuestos organicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126